ConvEyXO Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
2
ConvEyXO General Information
Description
Developer of anti-inflammatory and anti-aging therapeutics designed to address unmet medical needs by utilizing extracellular vesicles (EVs). The company focuses on industrializing EV manufacturing using a three-dimensional printed fixed bed, enabling pharmaceuticals as well as biotech firms to produce engineered exosomes, combining cost-effective manufacturing.
Contact Information
Website
conveyxo.comCorporate Office
- BioPark Charleroi Biotech 4
- Rue Clément Ader 10
- 6041 Charleroi
- Belgium
Corporate Office
- BioPark Charleroi Biotech 4
- Rue Clément Ader 10
- 6041 Charleroi
- Belgium
ConvEyXO Timeline
ConvEyXO Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 02-Oct-2025 | Completed | Generating Revenue | |||
| 3. Seed Round | 01-Aug-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 29-Jul-2022 | $3.06M | $5.43M | Completed | Generating Revenue | |
| 1. Early Stage VC | 02-Jul-2020 | $2.36M | $2.36M | Completed | Generating Revenue |
ConvEyXO Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Class A | 32,288 | $1.000000 | $65.05 | $65.05 | 1x | $65.05 | 12.03% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ConvEyXO Patents
ConvEyXO Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4759411-A1 | Method for loading biological particles with a molecule of interest | Pending | 16-Dec-2024 | ||
| WO-2026131650-A1 | Method for loading biological particles with a molecule of interest | Pending | 16-Dec-2024 | ||
| EP-4656187-A1 | Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles | Inactive | 30-May-2024 | ||
| WO-2025247999-A1 | Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles | Pending | 30-May-2024 | ||
| EP-4644537-A1 | Targeted extracellular vesicle | Inactive | 30-Apr-2024 | C12N5/0663 |
ConvEyXO Signals
ConvEyXO Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Saudi Biotechnology Accelerator | Accelerator/Incubator | |||
| Carbon ( Belgium ) | Venture Capital | Minority |
ConvEyXO FAQs
-
When was ConvEyXO founded?
ConvEyXO was founded in 2019.
-
Where is ConvEyXO headquartered?
ConvEyXO is headquartered in Charleroi, Belgium.
-
What is the size of ConvEyXO?
ConvEyXO has 50 total employees.
-
What industry is ConvEyXO in?
ConvEyXO’s primary industry is Drug Discovery.
-
Is ConvEyXO a private or public company?
ConvEyXO is a Private company.
-
What is ConvEyXO’s current revenue?
The current revenue for ConvEyXO is .
-
How much funding has ConvEyXO raised over time?
ConvEyXO has raised $6.45M.
-
Who are ConvEyXO’s investors?
Saudi Biotechnology Accelerator and Carbon ( Belgium ) have invested in ConvEyXO.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process